Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H19N3O4S.C6H14N2O2 |
| Molecular Weight | 495.592 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCCC[C@H](N)C(O)=O.CC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CCC=CC3)C2=O)C(O)=O
InChI
InChIKey=NTKRAGMAXIPNKX-SSDGIDNNSA-N
InChI=1S/C16H19N3O4S.C6H14N2O2/c1-8-7-24-15-11(14(21)19(15)12(8)16(22)23)18-13(20)10(17)9-5-3-2-4-6-9;7-4-2-1-3-5(8)6(9)10/h2-3,6,10-11,15H,4-5,7,17H2,1H3,(H,18,20)(H,22,23);5H,1-4,7-8H2,(H,9,10)/t10-,11-,15-;5-/m10/s1
| Molecular Formula | C16H19N3O4S |
| Molecular Weight | 349.405 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C6H14N2O2 |
| Molecular Weight | 146.1876 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/mtm/cephradine.html | http://www.medicinenet.com/cephradine-oral/article.htm | https://www.ncbi.nlm.nih.gov/pubmed/4684646
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/mtm/cephradine.html | http://www.medicinenet.com/cephradine-oral/article.htm | https://www.ncbi.nlm.nih.gov/pubmed/4684646
Cephradine is a semisynthetic cephalosporin antibiotic. Cephradine is active against the following organisms in vitro: Group A beta-hemolytic streptococci; Staphylococci, including coagulase-positive, coagulase-negative, and penicillinase-producing strains; Streptococcus pneumoniae (formerly Diplococcus pneumoniae); Escherichia coli; Proteus mirabilis; Klebsiella species; Hemophilus influenza. It works by stopping the growth of bacteria. It is used to treat a wide variety of bacterial infections (e.g., skin, ear, respiratory and urinary tract infections). Pseudomembranous colitis has been reported in patients receiving cephradine both orally and intravenously. Diarrhea generally starts 1 to 16 days after starting cephradine therapy. Gastrointestinal side effects have included nausea, vomiting. Hypersensitivity reactions have included rash, urticaria, pruritus, and joint pain. Bacteriostats may interfere with the bactericidal action of cephalosporins in acute infection; other agents, e.g., aminoglycosides, colistin, polymyxins, vancomycin, may increase the possibility of nephrotoxicity.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 30.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1974 |
|||
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1974 |
|||
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1974 |
|||
| Curative | VELOSEF '125' Approved UseCephradine is indicated in the treatment of the following infections: RESPIRATORY TRACT INFECTIONS (e.g., tonsillitis, pharyngitis, and lobar pneumonia) caused by group A beta-hemolytic streptococci and S. pneumoniae (formerly D. pneumonia). OTITIS MEDIA caused by group A beta-hemolytic streptococci, S. pneumoniae (formerly D. pneumoniae), H. influenzae, and staphylococci. SKIN AND SKIN STRUCTURE INFECTIONS caused by staphylococci (penicillin-susceptible and penicillin-resistant) and beta-hemolytic streptococci. URINARY TRACT INFECTIONS, including prostatitis, caused by E. coli, P. mirabilis, Klebsiella species, and enterococci (S. faecalis). Launch Date1974 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
17.7 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEPHRADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
27.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEPHRADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.61 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/848940/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
CEPHRADINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Uropathogen resistance to antibiotic prophylaxis in urinary tract infections. | 2010-06 |
|
| Colorimetric detection of cephradine in pharmaceutical formulations via fluorosurfactant-capped gold nanoparticles. | 2010-04-15 |
|
| Traumatic optic neuropathy accompanying orbital grease gun injury. | 2010-04 |
|
| Rate of conversion and complications of laparoscopic cholecystectomy in a tertiary care center in Saudi Arabia. | 2010-03-12 |
|
| A survey of the management of urinary tract infection in children in primary care and comparison with the NICE guidelines. | 2010-01-26 |
|
| Avian colibacillosis and salmonellosis: a closer look at epidemiology, pathogenesis, diagnosis, control and public health concerns. | 2010-01 |
|
| Selective densitometric determination of four alpha-aminocephalosporins using ninhydrin reagent. | 2010-01 |
|
| Rapid and simple method for determination of cephradine in human plasma using liquid chromatography-tandem mass spectrometry (LC-MS/MS): application to the bioequivalence study. | 2009-12-01 |
|
| [Analysis of multiple cephalosporins in blood and urine by HPLC]. | 2009-12 |
|
| [Kneading and dispersing manipulation in treatment of early-stage acute mastitis: a randomized controlled trial]. | 2009-12 |
|
| [Microcalorimetric investigation of two cephalosporins on colon bacteria activity]. | 2009-10 |
|
| [Antibiotic consumption and antimicrobial susceptibility evolution in the Centro Hospitalario Pereira Rossell in methicillin resistant Staphylococcus aureus era]. | 2009-10 |
|
| Study on the binding behavior of lysozyme with cephalosporin analogues by fluorescence spectroscopy. | 2009-09 |
|
| A study of the chemiluminescence behavior of cephalosporins with luminol and its analytical application. | 2009-08 |
|
| Antibiotic susceptibility pattern of Staphylococcus epidermidis. | 2009-07 |
|
| High macrolide resistance in Streptococcus pyogenes strains isolated from children with pharyngitis in China. | 2009-05 |
|
| Antibiotic susceptibility of thermo-tolerant Escherichia coli 2 isolated from drinking water of Khairpur City, Sindh, Pakistan. | 2009-04-15 |
|
| Lack of interaction between the peptidomimetic substrates captopril and cephradine. | 2009-03 |
|
| [Study of cefadroxil and cephradine charge transfer process by fluorescence quenching method]. | 2009-02 |
|
| Antibiotics for mastitis in breastfeeding women. | 2009-01-21 |
|
| Kinetic spectrophotometric determination of certain cephalosporins in pharmaceutical formulations. | 2009 |
|
| Adverse drug reactions in hospital in-patients: a prospective analysis of 3695 patient-episodes. | 2009 |
|
| Rhinoscleroma: case report. | 2008-12-19 |
|
| Effects of treatment with antimicrobial agents on the human colonic microflora. | 2008-12 |
|
| Human case of Rickettsia felis infection, Taiwan. | 2008-12 |
|
| Characteristics of Streptococcus pyogenes strains isolated from Chinese children with scarlet fever. | 2008-12 |
|
| Cranial osteomyelitis: a late complication of a dental infection. | 2008-12 |
|
| Pharmacokinetic study of cephradine in Pakistani healthy male volunteers. | 2008-10 |
|
| Studies on diseased freshwater prawn Macrobrachium rosenbergii infected with Vibrio vulnificus. | 2008-09-01 |
|
| A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. | 2008-08 |
|
| Aeromonas salmonicida peritonitis after eating fish in a patient undergoing CAPD. | 2008-05-14 |
|
| Quantitative prediction of oral absorption of PEPT1 substrates based on in vitro uptake into Caco-2 cells. | 2008-04-16 |
|
| Plasmid-mediated quinolone resistance in Salmonella enterica, United Kingdom. | 2008-02 |
|
| Risk of major bleeding during concomitant use of antibiotic drugs and coumarin anticoagulants. | 2008-02 |
|
| Biomimetic apatite coatings on titanium coprecipitated with cephradine and salviae miltlorrhizae. | 2008-02 |
|
| [Prophylactic use of antibiotics in selective colorectal operation: a randomized controlled trial]. | 2008-01-15 |
|
| Development of intestinal bifidobacteria and lactobacilli in breast-fed neonates. | 2007-10 |
|
| Use of SDS micelles for improving sensitivity, resolution, and speed in the analysis of beta-lactam antibiotics in environmental waters by SPE and CE. | 2007-09 |
|
| Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. | 2007-07-15 |
|
| Cephradine antacids interaction studies. | 2007-07 |
|
| Determination of beta-lactam antibiotics in milk using micro-flow chemiluminescence system with on-line solid phase extraction. | 2007-06-05 |
|
| [Genotypes of Staphylococcus aureus strains with methicillin resistant phenotype]. | 2007-05 |
|
| Characterization of beta-lactamases from urinary isolates of Escherichia coli in Tehran. | 2007-04 |
|
| A case of inadvertent anterior chamber and corneal stromal injection with antibiotics during cataract operation. | 2006-12 |
|
| Microplate assay for inhibitors of the transpeptidase activity of PBP1b of Escherichia coli. | 2006-12 |
|
| Controlled drug delivery system based on magnetic hollow spheres/polyelectrolyte multilayer core-shell structure. | 2006-10-20 |
|
| Increasing single and multi-antibiotic resistance in Shigella species isolated from shigellosis patients in Sana'a, Yemen. | 2006-08 |
|
| Chemiluminescence flow-injection analysis of beta-lactam antibiotics using the luminol-permanganate reaction. | 2006-06-23 |
|
| [Bacterial pathogens and resistance patterns in community acquired pediatric urinary tract infection: experience of 152 cases]. | 2006-04 |
|
| Properties and active substance release kinetics from gelatin-alginate matrices. | 2006 |
Patents
Sample Use Guides
For respiratory tract infections (other than lobar pneumonia) and skin and skin structure infections, the usual dose is 250 mg every 6 hours or 500 mg every 12 hours.
For lobar pneumonia, the usual dose is 500 mg every 6 hours or 1 g every 12 hours.
For uncomplicated urinary tract infections, the usual dose is 500 mg every 12 hours. In more serious urinary tract infections, including prostatitis, 500 mg every 6 hours or 1 g every 12 hours may be administered.
Larger doses (up to 1 g every 6 hours) may be given for severe or chronic infections.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:56:41 GMT 2025
by
admin
on
Mon Mar 31 17:56:41 GMT 2025
|
| Record UNII |
41BJN3H129
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
68641-66-7
Created by
admin on Mon Mar 31 17:56:41 GMT 2025 , Edited by admin on Mon Mar 31 17:56:41 GMT 2025
|
PRIMARY | |||
|
71587237
Created by
admin on Mon Mar 31 17:56:41 GMT 2025 , Edited by admin on Mon Mar 31 17:56:41 GMT 2025
|
PRIMARY | |||
|
41BJN3H129
Created by
admin on Mon Mar 31 17:56:41 GMT 2025 , Edited by admin on Mon Mar 31 17:56:41 GMT 2025
|
PRIMARY | |||
|
DTXSID90218733
Created by
admin on Mon Mar 31 17:56:41 GMT 2025 , Edited by admin on Mon Mar 31 17:56:41 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |